Pulse Biosciences Consensus Price Target Increased 12.27% to $51.82
The average one-year price target for Pulse Biosciences (NASDAQCM:PLSE) has been revised to $51.82 / share. This is an increase of 12.27% from the prior estimate of $46.16 dated August 25, 2026. These figures represent the aggregate consensus of analyst targets and do not constitute a recommendation orinvestment adviceby Fintel.
Separately, the latest targets range from a low of $35.35 to a high of $76.65 / share. The average price target represents a decrease of 6.11% from the latest reported closing price of $55.19 / share, as of September 15, 2026. The target range has widened from a prior range of $35.35 to $60.90, representing a target range width change of +61.64%.
The consensus target has experienced three consecutive upward revisions. Looking at the target history, the mean target was $31.28 on June 30, 2026, rising to $32.98 on August 4, 2026, and $46.16 on August 28, 2026, before reaching the current $51.82 on September 16, 2026. This represents a target change of +65.65% since the 90-day baseline date of June 8, 2026. Over the observed twelve-month period, the mean target reached a high of $51.82 on September 16, 2026, and a low of $22.44 on January 14, 2026.
Pulse Biosciences is a U.S.-based company operating within the biomedical sector, specializing in therapeutic technologies utilizing its proprietary Nano-Pulse Stimulation (NPS) platform, including its CellFX System. Analyst sentiment remains positive, with a total of 10 recommendations as of September 1, 2026, consisting of 3 strong buy, 6 buy, and 1 hold recommendations, representing a 90.0% positive ratio. Recent rating actions include Freedom Capital Markets initiating coverage with a Buy grade on September 9, 2026, and Needham initiating coverage with a Buy grade on August 17, 2026.
Within the broader Health Care Equipment sub-industry, coverage includes 23 companies, where 4 experienced raised targets, 4 were lowered, and 15 remained unchanged, resulting in a median sub-industry target revision of 0.00%.
| Company Name | Target revision | Implied change |
|---|---|---|
| InMode | 0.00% | +10.75% |
| Merit Medical Systems | +1.18% | +19.98% |
| SkinHealth Systems | 0.00% | +49.75% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.